BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 56 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $9,507,115 | -30.7% | 9,730,000 | -30.3% | 0.01% | -30.0% |
Q2 2023 | $13,718,574 | -2.9% | 13,965,000 | 0.0% | 0.02% | -4.8% |
Q1 2023 | $14,126,994 | -7.3% | 13,965,000 | -1.7% | 0.02% | -12.5% |
Q4 2022 | $15,240,971 | +8.3% | 14,205,000 | 0.0% | 0.02% | +4.3% |
Q3 2022 | $14,075,000 | -17.0% | 14,205,000 | -17.1% | 0.02% | -11.5% |
Q2 2022 | $16,958,000 | +19.6% | 17,129,000 | +20.6% | 0.03% | +36.8% |
Q1 2022 | $14,179,000 | – | 14,205,000 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SHENKMAN CAPITAL MANAGEMENT INC | 30,138,000 | $29,510,000 | 3.72% |
PFM Health Sciences, LP | 45,910,000 | $46,002,000 | 1.72% |
Cheyne Capital Management (UK) LLP | 2,320,000 | $2,330,000 | 1.47% |
ADVENT CAPITAL MANAGEMENT /DE/ | 41,077,000 | $41,277,000 | 0.66% |
SSI INVESTMENT MANAGEMENT LLC | 9,071,000 | $9,068,000 | 0.50% |
PALISADE CAPITAL MANAGEMENT, LP | 14,548,000 | $14,612,000 | 0.34% |
RWC Asset Management LLP | 7,500,000 | $7,552,000 | 0.21% |
KBC Group NV | 400,000 | $40,316,000 | 0.15% |
PROSPECTOR PARTNERS LLC | 1,000,000 | $1,000,000 | 0.12% |
MACKAY SHIELDS LLC | 11,822,000 | $11,816,000 | 0.10% |